Literature DB >> 17179659

The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.

Daniele Provenzano1, Pavol Kovác, William F Wade.   

Abstract

Cholera, a diarrheal disease, is known for explosive epidemics that can quickly kill thousands. Endemic cholera is a seasonal torment that also has a significant mortality. Not all nations with extensive rural communities can achieve the required infrastructure or behavioral changes to prevent epidemic or endemic cholera. For some communities, a single-dose cholera vaccine that protects those at risk is the most efficacious means to reduce morbidity and mortality. It is clear that our understanding of what a protective cholera immune response is has not progressed at the rate our understanding of the pathogenesis and molecular biology of cholera infection has. This review addresses V. cholerae lipopolysaccharide (LPS)-based immunogens because LPS is the only immunogen proven to induce protective antibody in humans. We discuss the role of anti-LPS antibodies in protection from cholera, the importance and the potential role of B cell subsets in protection that is based on their anatomical location and the intrinsic antigen-receptor specificity of various subsets is introduced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179659     DOI: 10.1111/j.1348-0421.2006.tb03866.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  8 in total

1.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 2.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

3.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

4.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

5.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

6.  IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.

Authors:  Jae Seung Yang; So Jung An; Mi Seon Jang; Manki Song; Seung Hyun Han
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

7.  Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate.

Authors:  Mahboube Bahroudi; Bita Bakhshi; Sara Soudi; Shahin Najar-Peerayeh
Journal:  Stem Cell Res Ther       Date:  2021-11-03       Impact factor: 6.832

8.  Constitutive type VI secretion system expression gives Vibrio cholerae intra- and interspecific competitive advantages.

Authors:  Daniel Unterweger; Maya Kitaoka; Sarah T Miyata; Verena Bachmann; Teresa M Brooks; Jessica Moloney; Oscar Sosa; David Silva; Jorge Duran-Gonzalez; Daniele Provenzano; Stefan Pukatzki
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.